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the setting of clinical investigation. This report summa-
rizes these 30 years of clinical cardiac transplantation at
our institution by a team that has remained essentially
unchanged during this period. 
T he first human cardiac transplant operation atStanford University Medical Center was performed
on January 6, 1968.1 It represented the translation of
more than a decade of laboratory experimentation into
Background: The experience with 30 years of cardiac transplantation at
Stanford University Medical Center was reviewed. A total of 954 trans-
plants were performed in 885 patients. Patients were divided into 3
groups based on immunosuppression received: group I, no cyclosporine
(INN: ciclosporin) (n = 201) (January 1968–November 1980); group II,
cyclosporine (n = 248) (December 1980–June 1987); and group III,
cyclosporine + OKT3 (n = 436) (July 1987–March 1998). Results: The 1-,
5-, and 10-year actuarial survivals were 68%, 41%, and 24% (group I);
80%, 57%, and 37% (group II); and 85%, 68%, and 46% (group III) (I
vs II, P < .01; I vs III, P < .005; and II vs III, P < .005). The 1-, 5-, and
10-year actuarial death rates from rejection were 8%, 12%, and 14%
(group I); 5%, 7%, and 7% (group II); and 2%, 5%, and 5% (group III)
(I vs II, P = not significant; I vs III, P < .005; and II vs III, P < .005). The
1-, 5-, and 10-year actuarial death rates from infection were 25%, 43%,
and 50% (group I); 8%, 17%, and 29% (group II); and 6%, 11%, and
16% (group III) (I vs II, P < .005; I vs III, P < .005; and II vs III, P <
.05). The 1-, 5-, and 10-year actuarial death rates from graft coronary
artery disease were 0%, 5%, and 13% (group I); 0%, 12%, and 19%
(group II); and 1%, 6%, and 9% (group III) (I vs II, P < .01; I vs III, P
< .005; and II vs III, P = not significant). There have been 69 retrans-
plants in 67 patients with 1-, 5-, and 10-year actuarial survivals of 49%,
27%, and 15%, respectively. Conclusions: The evolution of 3 decades of
experience with cardiac transplantation has resulted in improved over-
all survival. The incidence of rejection and of death from infection and
graft coronary artery disease have decreased over time, primarily as a
result of improvements in immunosuppression and in the prevention
and treatment of infection. Continued advances in perioperative man-
agement and the development of more specific, less toxic immunosup-
pressive agents could further refine this initial experience and improve
the survival and quality of life of patients after cardiac transplantation.
(J Thorac Cardiovasc Surg 1999;117:939-51)
Robert C. Robbins, MD
Clifford W. Barlow, MD
Philip E. Oyer, MD
Sharon A. Hunt, MD
Joan L. Miller, RN
Bruce A. Reitz, MD
Edward B. Stinson, MD
Norman E. Shumway, MD
From the Department of Cardiothoracic Surgery, Stanford University
School of Medicine, Falk Cardiovascular Research Center,
Stanford, Calif.
Read at the Seventy-eighth Annual Meeting of The American
Association for Thoracic Surgery, Boston, Mass, May 3-6, 1998.
Received for publication May 8, 1998; revisions requested Aug 13,




THIRTY YEARS OF CARDIAC TRANSPLANTATION AT STANFORD UNIVERSITY
Address for reprints: Robert C. Robbins, MD, Falk Cardiovascular
Research Center, Stanford University School of Medicine,
Stanford, CA 94305-5407. 
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/6/97382
Methods
Patients. The Stanford Transplant Database and records of
all cardiac transplants performed at Stanford University
Medical Center from 1968 to 1998 were reviewed. Patients
were divided into groups on the basis of the date of trans-
plantation and the core immunosuppressive protocols used:
group I, no cyclosporine (INN: ciclosporin) (pre-CSA) (n =
201) (January 1968–November 1980); group II, CSA (n =
248) (December 1980–June 1987); group III, CSA + OKT3
(n = 436) (July 1987–March 1998). A total of 954 transplants
have been performed in 885 patients, including 69 retrans-
plants in 67 patients. The number of procedures performed in
each group is listed in Table I. Detailed analysis was per-
formed on 807 patients because complete data were not avail-
able for 78 patients who received primary transplants.
Retransplant patients were initially included in survival data
analysis from the time of their primary transplant. They were
subsequently withdrawn alive from the primary database and
analyzed in a separate retransplant cohort after retransplanta-
tion. Additionally, independent analysis was made for adult
patients (19-70 years of age) and pediatric patients (birth-18
years of age). Selected donor and recipient characteristics for
adult patients are listed in Table II.
Recipient diagnoses for each group are given in Table III.
Operative techniques. The donor cardiectomy and the
technique of cardiac replacement have not changed signifi-
cantly in the past 30 years.2 However, bicaval anastomoses3
have been performed in 75 of the last 224 cardiac transplants.
All donor hearts have been preserved with cold hyperkalemic
crystalloid Stanford cardioplegic solution and cold storage
(saline solution at 3°C-4°C) during transportation.
Immunosuppression. Group I patients received various
combinations of azathioprine, prednisone, and polyclonal
rabbit antithymocyte globulin (Stanford). Group II patients
received various combinations of cyclosporine, azathioprine,
prednisone, and polyclonal rabbit antithymocyte globulin or
polyclonal horse antithymocyte globulin (ATGAM, Upjohn
Co, Kalamazoo, Mich) for induction therapy. All group III
patients were treated with cyclosporine, azathioprine, pred-
nisone, and the monoclonal antibody OKT3 (Ortho
Pharmaceutical Corp, Raritan, NJ) for induction therapy.
Additionally, since 1989 group III patients have received
cytomegalovirus (CMV) prophylaxis with gancyclovir4 if
either donor or recipient was CMV seropositive. Diltiazem
has been used in most patients since 19905 and lipid-lowering
agents since 1993 in an attempt to reduce graft coronary
artery disease (CAD). Subsets of patients have been convert-
ed to mycophenolate (n = 54), tacrolimus (n = 10), or a com-
bination of the 2 drugs (n = 38) as alternatives to cyclosporine
and azathioprine because of persistent rejection or adverse
side-effects. Total lymphoid irradiation (n = 28) and
methotrexate (n = 29) have been used for recalcitrant rejec-
tion in a subset of group III patients.6
Rejection has been monitored by endomyocardial biopsy
since 1972.7 Echocardiography has been used for the assess-
ment of myocardial performance and screening for rejection
since 1987.8 Recently, a small number of group III patients (n
< 20) have undergone plasmapheresis for myocardial dys-
function in the absence of biopsy evidence of cellular rejec-
tion.
Follow-up. Patients have been closely monitored by their
primary care physicians and by the posttransplant service
with detailed longitudinal data entered in the Stanford
Transplant Database. They have undergone extensive annual
evaluations consisting of right and left heart catheterization,
endomyocardial biopsy, echocardiography, coronary angiog-
raphy, and more recently intravascular coronary ultrasonog-
raphy. The mean follow-up time for the entire series was 4.93
± 4.74 years. The actuarial incidence of death (all causes) and
cause-specific death, rejection (diagnosed by endomyocar-
dial biopsy or autopsy), infection, graft CAD (diagnosed by
angiography and/or autopsy), lymphoid malignancy, and
nonlymphoid malignancy has been recorded in most (>90%)
patients.
Statistical analysis. Continuous variables are reported as
the mean ± 1 SD and the range. Comparisons between con-
tinuous variables were made with an unpaired 2-tailed t test
and discrete variables were compared with the continuity-
adjusted c 2 test. Actuarial life-table data were calculated by
the Cutler-Ederer method.9 Time-related event-free rates are
reported from actuarial estimates as the mean ± standard
error. Comparisons between actuarial curves were made by
the Gehan method.10
Results
Adult survival. Recipient age at the time of trans-
plantation, donor age, waiting time on the transplant
list, graft ischemic time, and the time to first rejection
have all significantly increased over the 30-year period,
whereas the length of postoperative hospital stay has
significantly decreased over time in the adult patients
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Table I. Number of cardiac transplants in each cohort
Group I Group II Group III 
(1968-1980): pre-CSA (1981-1987):CSA (1988-1998):CSA and OKT3 Total
Total No. of transplants 220 272 462 954
First transplants 201 248 436 885
Redo transplants 19 24 26 69
CSA, Cyclosporine.
(Table II). A significant increase in the number of
female recipients was observed from group I to group
II; however, there was no difference in actuarial sur-
vivals for male recipients compared with female recipi-
ents in any group. The actuarial survival was signifi-
cantly better in group II recipients who received hearts
from donors less than 30 years of age than from donors
over 30 years of age (P < .05). Such a difference, how-
ever, was not observed in group III recipients.
Additionally, there was no statistically significant dif-
ference in the actuarial rate of death from graft CAD for
older (>30 years of age) donor hearts in either group.
There were 106 total deaths in 115 group I patients
(18 early [within 90 days of operation], 88 late), 168 in
231 group II patients (32 early, 136 late), and 122 in
349 group III patients (24 early, 98 late) (Tables IV and
V). The early operative mortality rates (within 90 days
of operation) were 16% (group I), 14% (group II), and
7% (group III) (I vs II, P = NS*; I vs III, P < .05; II vs
III, P < .05). The 1-, 5-, and 10-year actuarial survivals
were 68%, 41%, and 24% (group I); 80%, 57%, and
37% (group II); and 85%, 68%, and 46% (group III)
(Fig 1). A statistically significant increase in survival
was observed in the group III patients as compared
with the other groups. The actuarial survival of group II
patients was better than that of group I patients, but the
statistical significance of the difference was not as dra-
matic as the difference from group III survival (I vs II,
P < .01; I vs III, P < .005; and II vs III, P < .005). A
total of 150 patients have survived 10 years, 38 patients
have survived 15 years, and 8 patients have survived 20
years after transplantation, with the longest survival
The Journal of Thoracic and
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Table II. Demographics of recipients and donors for first-time adult cardiac transplant recipients
Group I Group II Group III 
Variable (n = 115) (n = 231) (n = 349) Comparisons
Recipient age (y) 39.5 ± 10.6 (19-56) 41.7 ± 10.6 (18-62) 49.5 ± 11.4 (18-70) †‡
Donor age (y) NA 23.6 ± 6.4 (12-44) 29.4 ± 10.8 (11-54) ‡
Recipient gender (M/F) 104/11 187/44 290/59
Donor gender (M/F) 90/25 192/39 255/94
CMV status (27-NA) (14-NA)
D–;R– NA 59 (29%) 60 (18%)
D+; R+ NA 64 (31%) 112 (33%)
D–;R+ NA 51 (25%) 93 (28%)
D+; R– NA 30 (15%) 70 (21%)
Previous sternotomy 32/83 78/153 157/192
(yes/no)
Preop support (124-NA)
None NA 70 (65%) 243 (70%)
Inotropic drugs NA 24 (23%) 82 (23%)
IABP NA 9 (8%) 3 (1%)
LVAS NA 4 (4%) 21 (6%)
Waiting time (d) 41.9 ± 34.3 (2-121) 45.7 ± 54.2 (1-291) 183.7 ± 204.7 (1-999) †‡
Ischemic time (min) 92.2 ± 54.4 (15-192) 131.4 ± 51.4 (38-260) 170.0 ± 47.8 (40-309) *†‡
CPB time (min) 94.6 ± 23.1 (57-143) 111.7 ± 32.4 (61-222) 115.0 ± 34.6 (32-319) *†
LOS (d) 69.0 ± 35.1 (2-236) 36.7 ± 21.0 (1-175) 20.1 ± 30.8 (1-379) *†‡
Time to first rejection (d) 33.9 ± 51.9 (6-428) 46.9 ± 127.6 (2-1073) 85.0 ± 259.7 (5-3330) †‡
Data are mean ± SD (range). M, Male; F, female; CMV, cytomegalovirus; D, donor; R, recipient; +, positive; –, negative; NA, not available; IABP, intra-aortic bal-
loon pump; LVAS, left ventricular assist system; CPB, cardiopulmonary bypass; LOS, length of stay.
*P < .05, group I versus group II.
†P < .05, group I versus group III.
‡P < .05, group II versus group III.
Table III. Diagnoses in adult first-time cardiac trans-
plant recipients 
Diagnosis Group I Group II Group III
Coronary artery disease 51 (44%) 100 (43%) 153 (44%)
Idiopathic cardiomyopathy 59 (51%) 96 (41%) 139 (40%)
Viral cardiomyopathy 1 (0.8%) 13 (5.5%) 12 (3%)
Postpartum cardiomyopathy 0 7 (3%) 5 (1.4%)
Familial cardiomyopathy 2 (1.7%) 5 (2%) 6 (1.7%)
Congenital defect 1 (0.8%) 3 (1.3%) 6 (1.7%)
Valvular disease 0 0 18 (5.2%)
Other 1 (0.8%) 7 (3%) 10 (2.9%)
Total 115 231 349
*NS = Not significant.
time being 23.5 years. Previous cardiac surgery had
been performed in 267 of 695 (38%) adult recipients,
but there was no significant difference in early (<90
day) operative or late actuarial survival as compared
with recipients who had not undergone previous car-
diac operations.
Rejection. The 1-, 5-, and 10-year actuarial death
rates from rejection were 8%, 12%, and 14% (group I);
5%, 7%, and 7% (group II); and 2%, 5%, and 5% (group
III) (Fig 2). The only significant improvement in death
from rejection was observed in the comparison between
group I and group III patients (I vs II, P = NS; I vs III,
P < .05; and II vs III, P = NS). The rates for freedom
from rejection at 1, 5, and 10 years were 11%, 10%, and
10% (group I); 10%, 6%, and 6% (group II); and 23%,
19%, and 15% (group III) (Fig 3). Although the major-
ity of the patients had at least one episode of rejection,
the incidence of rejection was significantly reduced in
the group III patients compared with the other groups (I
vs II, P = NS; I vs III, P < .005; II vs III, P < .005).
Infection. The 1-, 5-, and 10-year actuarial death
rates from infection were 25%, 43%, and 50% (group
I); 8%, 17%, and 29% (group II); and 6%, 11%, and
16% (group III) (Fig 4). These data demonstrate a pro-
gressive and significant decrease in the risk of death
from infection (I vs II, P < .005; I vs III, P < .005; and
II vs III, P < .05). The rates for freedom from any infec-
tion at 1, 5, and 10 years were 16%, 10%, and 10%
(group I); 21%, 10%, and 7% (group II); and 35%,
20%, and 19% (group III) (Fig 5). The incidence of
infection was significantly reduced in the group III
patients compared with the other groups (I vs II, P =
NS; I vs III, P < .005; and II vs III, P < .005).
The status of recipient and donor CMV serology was
compared only between groups II and III, because this
information was not available for group I patients.
There was no significant difference in actuarial survival
or death rates from rejection, infection, or graft CAD
for the combination of a CMV-negative recipient
receiving a heart from a CMV-negative donor. A sig-
nificant decrease in actuarial survival was observed
between the groups for any combination that included
either a seropositive recipient or donor compared with
the use of a seronegative graft in a seronegative recipi-
ent: R+/D+ (P < .05); R+/D– (P < .05); R–/D+ (P <
.005). The death rate due to infection was significantly
lower in the group III patients for CMV-positive recip-
ients receiving CMV-negative hearts (P < .05). A sig-
nificantly lower death rate from graft CAD was
observed in the group III CMV-positive recipients who
received a CMV-negative heart (P < .005). No signifi-
cant difference in the death rates from rejection
between the groups was observed for any recipient/
donor combination.
Graft CAD. The 1-, 5-, and 10-year actuarial death
rates from graft CAD were 0%, 5%, and 13% (group I);
0%, 12%, and 19% (group II); and 1%, 6%, and 9%
(group III) (Fig 6). The probability of death from graft
CAD was significantly higher for the group II patients
than for the other groups (I vs II, P < .05; I vs III, P =
NS; II vs III, P < .05). The rates for freedom from graft
CAD at 1, 5, and 10 years were 88%, 52%, and 43%
(group I); 94%, 71%, and 57% (group II); and 93%,
75%, and 67% (group III) (Fig 7). The incidence of
graft CAD was significantly reduced in the latter 2
groups compared with group I patients. No significant
difference, however, was observed between the group
II and III patients (I vs II, P < .01; I vs III, P < .005;
and II vs III, P = NS).
Lymphoproliferative and nonlymphoid malignant
disease. The 1-, 5-, and 10-year actuarial death rates
942 Robbins et al The Journal of Thoracic and
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Table IV. Causes of death (early < 90 days) for first-
time adult recipients
Group I Group II Group III 
Diagnosis (n = 115) (n = 231) (n = 349)
Infection 13 (72%) 14 (44%) 12 (50%)
Rejection 2 (11%) 6 (19%) 3 (12.5%)
Pulmonary embolus 0 1 (3%) 0
Pulmonary hypertension 2 (11%) 2 (6%) 1 (4%)
Cerebrovascular accident 1 (5.5%) 4 (12.5%) 1 (4%)
Graft failure 0 5 (15.5%) 3 (12.5%)
Bleeding 0 0 1 (4%)
Multisystem organ failure 0 0 3 (12.5%)
Total 18 32 24
Table V. Causes of death (late > 90 days) for first-
time recipients
Group I Group II Group III 
Diagnosis (n = 115) (n = 231) (n = 349)
Infection 40 (45%) 39 (28.5%) 26 (27%)
Rejection 10 (11%) 8 (6%) 11 (11%)
Coronary artery disease 14 (16%) 39 (28.5%) 21 (21%)
Lymphoid malignant disease 6 (7%) 10 (7%) 3 (3%)
Nonlymphoid malignant 6 (7%) 14 (10%) 11 (11%)
disease
Pulmonary failure 0 0 1 (1%)
Pulmonary embolus 1 (1.1%) 1 (0.7%) 0
Cerebrovascular accident 0 4 (3%) 1 (1%)
Bleeding 0 1 (0.7%) 1 (1%)
Renal failure 0 1 (0.7%) 1 (1%)
Other 11 (12.5%) 19 (14%) 22 (22%)
Total 88 136 98
from lymphoproliferative disease were 0%, 3%, and
11% (group I); 1%, 3%, and 6% (group II); 1%, 1%,
and 2% (group III). No statistically significant differ-
ence in the actuarial death rates from lymphoprolifera-
tive disease were observed among the groups (I vs II, P
= NS; I vs III, P < .10; II vs III, P < .10), nor was there
a difference in the incidence of death from nonlym-
phoid malignant disease among the groups.
Lymphoproliferative disease was the cause of death
in 19 patients (I, n = 6; II, n = 10; III, n = 3) and non-
lymphoid malignant disease in 31 patients (I, n = 6; II,
n = 14; III, n = 11) (Table V).
Recipient pretransplantation hemodynamic sta-
tus. The Novacor left ventricular assist system (LVAS;
Baxter Healthcare Corp, Novacor Div, Oakland, Calif)
has been implanted in 34 patients as a bridge to cardiac
replacement since 1984.11 Nine LVAS-supported
patients died before transplantation (multisystem organ
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Fig 1. Comparison of actuarial survival between groups. CSA, Cyclosporine.
Fig 2. Comparison of actuarial death rates from rejection between groups. CSA, Cyclosporine. NS, not significant.
failure, n = 6; hemorrhage, n = 2; thromboembolic
event, n = 1). Cardiac transplantation was performed in
the other 25 LVAS-supported patients with 1 early
death from infection (postoperative day 2) and 3 late
deaths from nonlymphoid malignant disease. The 1-,
5-, and 10-year actuarial survivals for this cohort of
patients were 92%, 78%, and 78%, respectively. 
A significantly higher actuarial survival was
observed in patients requiring hemodynamic support
(either mechanical or pharmacologic) (UNOS status 1
[United Network for Organ Sharing]) compared with
patients not requiring such support (UNOS status 2) in
group III (P < .05) without a significant increase in the
incidence of infection. However, there was no differ-
ence in actuarial survivals in group III patients who
received no preoperative inotropic support compared
with patients who received inotropic support alone, an
analysis which excludes the outstanding survival of the
944 Robbins et al The Journal of Thoracic and
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Fig 3. Comparison of actuarial freedom from rejection between groups. CSA, Cyclosporine; NS, Not significant.
Fig 4. Comparison of actuarial death rates from infection between groups. CSA, Cyclosporine.
LVAS-supported patients from the UNOS status 1
cohort. No significant difference in actuarial survival
was observed between group II UNOS status 1 patients
and UNOS status 2 patients. Actuarial survival was sig-
nificantly better for UNOS status 1 patients in group III
versus UNOS status 1 patients in group II (P < .005),
but no difference was noted for UNOS status 2 patients
between the groups.
Late reoperation. Eight patients have undergone tri-
cuspid valve replacement with a porcine bioprosthesis
for iatrogenic (biopsy-related) tricuspid regurgitation
and decompensated right heart failure. No deaths have
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Fig 5. Comparison of actuarial freedom from infection between groups. CSA, Cyclosporine; NS, not significant.
Fig 6. Comparison of actuarial death rates from graft coronary artery disease (CAD) between groups. CSA,
Cyclosporine; NS, not significant.
occurred in this cohort of patients and all have had symp-
tomatic improvement with resolution of ascites and
peripheral edema. Two patients required pericardiecto-
my for constrictive disease and 1 patient required donor
mitral valve replacement 10 years after transplantation
for mitral regurgitation from leaflet prolapse.
Retransplants. Detailed data were available for 66
of the 69 patients undergoing retransplantation.
Twenty-three procedures were performed early, within
30 days of the primary transplant operation (acute
rejection, n = 16; acute graft failure, n = 7), and 43
were performed late after primary cardiac transplanta-
946 Robbins et al The Journal of Thoracic and
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Fig 7. Comparison of actuarial freedom from graft coronary artery disease (CAD) between groups. CSA,
Cyclosporine; NS, not significant.
Fig 8. Actuarial survival of retransplant recipients.
tion (graft CAD, n = 39; constrictive disease, n = 3; late
graft failure, n = 1). The overall 1-, 5-, and 10-year
actuarial survivals for this cohort were 49%, 27%, and
15% (Fig 8). Stratification of the results of retransplan-
tation based on the timing of retransplantation demon-
strates that survival is better for patients undergoing
retransplantation for late graft failure than for early
graft failure; however, the 5- and 10-year survivals are
poor for both cohorts (3-month and 1-, 5-, and 10-year
survivals: 79%, 57%, 27%, and 18% [late] versus 48%,
35%, 26%, and 10% [early]).
Pediatric patients. Data were analyzed from the lat-
ter 2 groups because only 6 pediatric patients under-
went transplantation before 1980. The 1-, 5-, and 10-
year actuarial survivals of all patients less than 19 years
of age were 82%, 68%, and 52% (group II) and 73%,
63%, and 60% (group III) (Fig 9). No statistically sig-
nificant difference in actuarial survival was detected
between these groups.
Discussion 
The purpose of this review was to examine the
changes that have occurred in the cardiac transplant
program at Stanford over the past 30 years in an attempt
to identify features that have contributed to our current
results. The fact that so many variables have entered
into this equation, combined with the limitations of ret-
rospective assessment, ensure that the final analysis
will be observational at best. The mentality of the pro-
gram has combined radical persistence, even when
early success was limited, with a conservative method-
ical progression by a team whose core members have
remained constant and have worked together with hun-
dreds of contributors over the past 3 decades. The fol-
lowing comments will emphasize some of the high-
lights of this work in progress.
The conceptualization and development of the tech-
nique of orthotopic cardiac transplantation evolved
serendipitously from early investigations of myocardial
preservation. Several groups were experimenting with
various techniques of cardiac transplantation, which
included total cardiac replacement with separate pul-
monary venous and bicaval anastomoses,12 en bloc
heart and right lung transplantation,13 and en bloc heart-
lung replacement14 in the 1950s. Success was limited
primarily by technical difficulties with the pulmonary
venous and caval anastomoses. The preservation of bi-
atrial cuffs at the time of recipient cardiectomy first
described by Lower and Shumway2 in 1959 led to reli-
ably reproducible canine cardiac replacement and estab-
lished the foundation for over a decade of subsequent
experimental investigations of cardiac transplantation.
The consistent long-term survival of canine cardiac
transplant recipients immunosuppressed with pred-
nisone and azathioprine eventually justified the transla-
tion of laboratory experience into the experimental
phase of human cardiac transplantation at Stanford in
1968.15 Results during the first 5 years of clinical car-
diac transplantation was established that the operation
was a technically simple, safe, and reproducible proce-
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Fig 9. Comparison of actuarial survivals of pediatric patients in groups II and III. CSA, Cyclosporine; NS, not
significant.
dure and that the denervated human allograft could
support normal physical activity.16,17 Additional infor-
mation was documented concerning the hemodynamic
performance of the allograft.18 Consequently, the oper-
ative technique has remained essentially unchanged
since this initial period. Evolution of the program has
continued with gradual refinements in immunosuppres-
sion combined with improvements in the treatment and
prophylaxis of infection which, in turn, are obviously
dependent on the degree of immunosuppression.
During the early phase of the program, meticulous
attention to detail was required for any patient to sur-
vive through the initial period of cellular rejection.
Despite use of frequent electrocardiographic assess-
ment in conjunction with physical examination for the
diagnosis of rejection, a relatively high incidence of
death from infection and rejection persisted because of
an inability to fine-tune immunosuppression according
to the severity of rejection and level of success in treat-
ing rejection. The introduction of endomyocardial
biopsy in 19727 established an objective method for
diagnosing rejection, thereby providing evidence-based
guidance for the intensity of recipient immunosuppres-
sion. The introduction of lympholytic rabbit antithymo-
cyte globulin (ATG) in 1973 provided a potent, some-
what more targeted immunosuppressive strategy.19 The
almost simultaneous adoption of these 2 new modali-
ties constituted a major improvement in the immuno-
suppressive strategy. The enactment of laws codifying
brain death and the introduction of distant donor pro-
curement20 in 1973 were also incremental advances
contributing to the expansion of clinical experience.
The next major period of the program’s evolution
began in 1980 with the introduction of cyclosporine.21,22
The ability to provide potent and probably more selec-
tive long-term oral maintenance immunosuppression
resulted in significantly improved survival, primarily
through a reduction in infection-related deaths.
Improved treatment and prophylaxis of infection (eg,
Pneumocystis carinii infection) additionally contributed
to improved results during this period.23
On October 17, 1986, the US government decreed an
end to the experimental phase of human cardiac trans-
plantation by approving Medicare reimbursement for
the procedure at this institution.
The introduction of more specific and standardized
lympholytic induction therapy with the monoclonal
anti-CD3 antibody preparation OKT3 was initiated in
1987 and represented the next major change in the
immunosuppressive strategy of the program.24,25
Prolongation of the interval to the first episode of rejec-
tion has been the most obvious benefit of this approach
to immunosuppression. Contemporaneously, the pro-
phylaxis and treatment of CMV infection improved
with the liberal use of gancyclovoir4 and later of hyper-
immune globulin preparation.
The statistical analysis of results in the present study
is limited by the arbitrary division of patients into 3
cohorts based on the major alterations in the immuno-
suppressive protocol used. Several modalities have
been introduced and modified within each group, and
new modalities for the care of patients have been incor-
porated independent of the immunosuppressive proto-
col. Also, general progress has occurred over these
years in many areas that affect patient survival, such as
the diagnosis and treatment of infectious and malignant
complications. Despite these limitations of this analy-
sis, several important observations can be made.
Group III patients were significantly older at the time
of transplantation, received organs from older donors
with longer graft ischemic times, and waited longer
after selection for transplantation. However, they had
significantly higher early and long-term actuarial sur-
vivals than the other 2 groups. These results can be
attributed to a progressive decrease in the incidence of
rejection and death due to infection, but not death due
to rejection, which has always remained low.
Additionally, the incidence of graft CAD has progres-
sively decreased. Death related to graft CAD was high-
er for group II patients than for group III patients.
However, no significant change in the incidence of
graft CAD was observed between the group II and III
patients, suggesting that this disease process may have
been stabilized or retarded by the use of diltiazem and
lipid-lowering agents. A significant increase in actuari-
al survival was observed after the introduction of
cyclosporine in group II patients, as compared with
group I patients, but this significance was less dramat-
ic than the results observed for group III patients. The
improved survival in group II patients compared with
group I patients was predominately due to a dramatic
reduction in the death rate from infection, since there
was no significant decrease in operative or rejection-
related deaths.
The significantly prolonged time to first rejection in
group III patients can be directly attributed to the use of
OKT3. The virtual elimination of early perioperative
rejection combined with the current mentality of early
hospital discharge has been associated with shorter
hospital stays and a reduced incidence of infection
without any change in actuarial death rates from lym-
phoproliferative disease or nonlymphoid malignant
disease. Additionally, OKT3 induction therapy permits
the luxury of a gradual institution of cyclosporine in
the immediate postoperative period when renal insuffi-
ciency may be problematic, especially in this increas-
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ingly older group of patients. The aggressive prophy-
laxis and management of CMV disease in group III
patients also has contributed to improved survival by
virtue of a decreased incidence of infections and possi-
bly even rejection. Such derivative effects are difficult
to fully define but have almost certainly contributed to
enhancement of survival.
The major continuing limitation to the volume of car-
diac transplantation has been that of donor availability.
Despite intense public education in this regard, the
donor pool has remained static during this decade. This
fact emphasizes the need for strategies to assure opti-
mum use of donor grafts and may preclude, except in
rare circumstances, the use of hearts for retransplanta-
tion because of the relatively poor results obtained. In
a real sense, the issue of human organ donation is not a
medical one, but rather a societal one.
Many refinements in the care of cardiac transplant
patients have been incorporated at our institution over
the past 30 years. The sum of the components has been
more important than any single factor, as is the usual
case. Although results have progressively improved,
many limitations remain. The results of cardiac trans-
plantation will not approach the results of other cardiac
surgical procedures until nonspecific, poorly targeted
immunosuppression is replaced by highly specific
immunomodulation or the achievement of tolerance
induction.
We thank D. Craig Miller, MD, and Kathleen A. Moore for
their assistance with statistical analysis.
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Discussion
Dr Bartley P. Griffith (Pittsburgh, Pa). Rarely does one
have an opportunity to comment on a 30-year experience. It
is special for me because the topic is heart transplantation and
the report is from its originators. Dr Robbins, while you have
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just described remarkable progress, it is important for me to
acknowledge how well Dr Shumway, you, and his other
trainees, many of whom helped to lead this Society, have car-
ried the responsibility. During the early years poor results
brought criticism. Persistence led to incremental improve-
ment and the development of enabling endomyocardial biopsy
and antithymocyte globulin. 
An expanded experience that accrued during the 1970s,
combined with cyclosporine in 1980, permitted a striking
upgrade in prospects, chiefly due to reduced deaths by infec-
tion and fewer episodes of rejection. When the rest of the
world joined you at this milepost, it did so often without
proper understanding of your prior sweat equity. 
The Stanford program, however, remained humble and dis-
satisfied. As an inevitable consequence, results continued to
inch upward. In the 1990s, antiviral and alternative targeted
immunosuppression have improved the outlook further. It is
notable that 159 of 436 group III recipients, your most recent
cohort, received adjunctive therapy to the stated maintenance
immunosuppressive regimens. We and others join you with
recent improved survivals that are now associated with half-
life estimates of 9 years, certainly acceptable and far better
than the 5 years possible as recently as the early 1980s. I
would agree that multiple interrelating factors not obvious by
multivariate analysis are responsible. 
Dr Robbins, I do have some questions about statistical
methods used to infer the data in the manuscript. The reason
for the exclusion of 78 patients with incomplete follow-up is
unclear. Did they live? What groups were they from? When
combined with the 69 retransplantation patients who were
withdrawn from analysis alive, we have almost 17% of the
total experience “not” or perhaps incorrectly accounted for.
The large number of associations investigated between 5 out-
comes made it likely that false associations could be and
probably were found by chance. 
Why was the Gehan method used instead of the log rank
method to distinguish among the groups? This would have
had the effect of excessive weighting of early results over
later ones. 
Finally, your overall and group III incidence of transplan-
tation of status 1 patients is only 30%, far lower than the
national average of nearly 68% in 1996. How do you explain
the wellness of your recipients and the fact that the waiting
time, averaging only 183 days for group III patients, is less
than half the 559 days for UNOS status 2 recipients? 
Dr Robbins. Thank you, Dr Griffith, for those comments.
Let me take the last question first. Our waiting times are
shorter than the national average, and only 30% of our
patients undergo transplantation from the status 1 category. I
think that our transplant cardiologists, particularly led by
Michael Fowler, John Schroeder, and Randy Vagelos, have
frequently published data looking at aggressive angiotensin-
converting enzyme inhibition and b -blockade. Our philoso-
phy is to try to keep patients out of the hospital in the status
2 category. We do not list patients as status 1 until the maxi-
mum oxygen consumption is less than 14, and we make every
effort to keep them out of the hospital. We have been very
lucky in our OPO that we are able to perform transplants in
many of our patients who are in UNOS status 2. 
The 78 patients who were excluded were from group I. I
went back to our database primarily. Because we did not have
complete data on some of the first 78 patients, I chose to
leave them out of the analysis, but they are all from group I.
When patients undergo retransplantation, they go into a sep-
arate database and are analyzed separately. Your point is well
taken that they are basically conferred immortality when they
are taken out alive. 
This is a retrospective review and it includes all of the
problems associated with that type of analysis, which is com-
plicated by the fact that many things have changed over the
years. The arbitrary division of the patients into the 3 groups
certainly leaves us open for criticism, but that was the best
method I could devise.
Dr Adnan Cobanoglu (Portland, Ore). I would like to con-
gratulate Dr Robbins and the pioneers at Stanford University
for their outstanding efforts over the past 3 decades. This data
presented certainly represent a lot of sweat, late nights, early
mornings, and hard work over the past 30 years. 
I wanted to comment on the grouping of the patients. We
started our heart transplant program in Portland, Oregon, in
1985 with a group of patients analogous to your group II,
based on triple immunosuppression. Our regimen has
remained pretty much the same over the past 13 years. We
have used OKT3 only as necessary in those patients with pre-
existing renal dysfunction. Our 1-year, 5-year, and 10-year
survivals are 87%, 76%, and 59%, respectively. The reason I
mention this is that it is possible to achieve good late results
with the group II type immunosuppression regimen based on
triple immunosuppression that includes cyclosporine. 
I have a couple of questions. One is related to increased
early mortality in the group of patients who received donor
hearts from bigger, heavier donors. That, to me, seems some-
what contrary to the experience of others, in which smaller
donor size has caused problems with early mortality and
morbidity. 
Second, based on your experience with retransplantation,
should we really consider retransplantation seriously in this
era of ever-increasing donor paucity? If we do, who would be
the best candidates for retransplantation? Do you still do
retransplantations at Stanford? 
Any such discussion of cardiac transplantation has to
include some donor-related data and the concern about limit-
ed availability of donor organs. This continues to be the main
issue limiting our ability to perform transplantations. What
should we do to increase the available donor pool? 
Dr Robbins. I agree that many programs have good expe-
rience and good results without induction therapy. We at
Stanford have been very conservative and slow to change, but
we do acknowledge that excellent results can be obtained
without induction therapy. 
In terms of the heavier donor hearts, we redid the multi-
variable analysis and that did not fall out as one of the posi-
tive significant variables. I thought it was a bit strange also,
and we therefore reworked the multivariable analysis. 
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We have been disappointed with retransplantation even in
what appeared to be good-risk patients for graft CAD. For
acute graft failure I think the risks are prohibitive. Patients
undergoing retransplantation for early indications were early
in the experience, before LVASs were available. Today it is
possible that with LVAS support we can make these patients
better candidates. However, results were marginal even in the
candidates with graft CAD. For these reasons we have backed
off from retransplantation and would consider only a young
patient who has no other comorbidities. The most important
comorbidity is renal dysfunction. Thus for a young person
who was a good candidate in every other way, we would still
consider retransplantation. 
Donor availability, obviously, is still the limitation to
increasing the numbers of transplants. I think the only way to
improve that situation is through public education and then
possibly exploring xenotransplantation. 
Dr Roland Hetzer (Berlin, Germany). I rise to pay
homage to the unique achievement of the Stanford group. Not
only did they establish heart transplantation almost single-
handedly, but they also provided decisive stimuli in many
fields of medicine and beyond. By closely following the
Stanford protocols over the years, we have performed 1047
heart transplants, with a survival of approximately 50% at 10
years and 84 patients living longer than 10 years. Studying
those long-term survivors generated many questions that
need to be answered. I would like to ask Dr Robbins just 3 of
those questions, well knowing that they may be difficult to
deal with. 
First, are there any data that might define those patients
who are likely to become long-term survivors? 
Second, are there any concepts offering permanent social
aid, in particular to the young transplant patients, which
might enhance longevity and quality of life? 
Third, what is the estimated life expectancy of a patient
who is undergoing heart transplantation today?
Dr Robbins. Thank you, Dr Hetzer, for those comments.
More than 150 of our patients have survived more than 10
years, 38 more than 15 years, and 8 patients more than 20 years.
The longest survival was 23.5 years. I know of no data that will
identify which of the survivors will live longer. We did not have
enough numbers to look at, for instance, HLA matching. That
did not emerge as a significant reason for long-term survival.
We have evaluated these 150 patients who have survived more
than 10 years, and it is difficult to come up with an answer. 
I do not have a good answer regarding social aid, either. It
is very important for the patient to have a good, strong family
support system, because the patient is trading one disease for
another.
Regarding life expectancy, I have actuarial data suggesting
that about half of our patients will be alive at 10 years, just as
in your series. It is very difficult to project a life span for a
patient after transplantation. As Craig Miller always says, it
is binary logic, either 100% or 0%.
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